Prescribing paradigm shift? Applying the 2019 European Society of Cardiology-led guidelines on ‘diabetes, pre-diabetes, and cardiovascular disease’ to assess eligibility for sodium-glucose co-transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists as first-line monotherapy (or add-on to metformin monotherapy) in type 2 diabetes in Scotland
Thomas M. Caparrotta, Luke A. K. Blackbourn, Stuart J. McGurnaghan, John Chalmers, Robert Lindsay, Rory McCrimmon, John McKnight, Sarah Wild, John R. Petrie, Sam Philip, Paul M. McKeigue, David J. Webb, Naveed Sattar, Helen M. Colhoun (Lead / Corresponding author), Scottish Diabetes Research Network Epidemiology Group
Research output: Contribution to journal › Article › peer-review
Dive into the research topics of 'Prescribing paradigm shift? Applying the 2019 European Society of Cardiology-led guidelines on ‘diabetes, pre-diabetes, and cardiovascular disease’ to assess eligibility for sodium-glucose co-transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists as first-line monotherapy (or add-on to metformin monotherapy) in type 2 diabetes in Scotland'. Together they form a unique fingerprint.